

Appendix: Tables

1.	Sales January to June 2023 and 2022	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2023 and 2022	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2023 vs. YTD June 2022	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10
9.	Roche Group consolidated income statement for the six months ended 30 June 2023	11
10.	Roche Group core results reconciliation – Half Year 2023	12
11.	Divisional core results reconciliation – Half Year 2023	13
12.	Roche Group consolidated balance sheet	14
13.	Roche Group consolidated statement of cash flows	15

1. Sales January to June 2023 and 2022

CHF millions	Six months ended 30 June		% change	
	2023	2022	At CER	In CHF
Pharmaceuticals Division	22,681	22,347	8	1
United States	11,743	11,363	7	3
Europe	4,105	4,104	5	0
Japan	2,210	2,202	14	0
International*	4,623	4,678	9	-1
Diagnostics Division	7,098	9,948	-23	-29
Roche Group	29,779	32,295	-2	-8

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2023 and 2022

CHF millions	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022
Pharmaceuticals Div.	11,188	0	10,842	-6	12,362	9	11,699	9	10,982	7
United States	5,874	1	5,836	-6	6,123	1	5,853	6	5,890	7
Europe	2,032	-6	1,996	4	2,043	-3	2,071	5	2,034	5
Japan	865	3	827	-27	1,920	69	1,390	18	820	8
International*	2,417	4	2,183	-3	2,276	4	2,385	13	2,238	6
Diagnostics Division	4,662	0	3,900	-4	3,882	-9	3,623	-28	3,475	-17
Roche Group	15,850	0	14,742	-6	16,244	4	15,322	-3	14,457	0

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD June 2023 vs. YTD June 2022

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	3,200	15	2,346	13	584	13	-	-	270	28
Hemlibra	2,087	20	1,247	18	419	22	192	21	229	34
Perjeta	2,082	9	763	7	413	-5	109	3	797	20
Tecentriq	1,853	12	1,000	9	398	9	214	11	241	28
Actemra/RoActemra	1,296	-6	574	-11	383	-4	157	3	182	1
Xolair	1,031	4	1,031	4	-	-	-	-	-	-
Kadcyla	1,001	0	386	-4	298	-10	52	-13	265	24
Vabysmo	957	**	788	**	103	**	46	**	20	**
MabThera/Rituxan	882	-17	534	-20	96	-4	13	-14	239	-13
Herceptin	878	-19	176	-31	183	-17	17	-32	502	-14
Avastin	837	-21	256	-23	57	-48	177	-23	347	-10
Alecensa	758	10	221	11	148	4	107	6	282	14
Evryydi	705	48	255	16	241	66	45	34	164	105
Activase/TNKase	621	15	592	15	-	-	-	-	29	12
Ronapreve	550	2	-	-	-	-100	549	33	1	-99
Phesgo	517	69	209	57	240	57	-	-	68	216
Gazyva	402	22	194	25	111	24	20	-17	77	28
Polivy	353	114	124	65	80	84	108	182	41	339
Lucentis	299	-46	299	-46	-	-	-	-	-	-
Pulmozyme	238	-10	158	-11	39	-18	-	5	41	3
Enspryng	120	56	33	41	7	98	74	53	6	292
Rozlytrek	40	25	21	-1	8	49	4	25	7	167

Cotellic	29	26	14	94	6	-24	-	-	9	12
Lunsumio	28	-	24	-	4	-	-	-	-	-
Xofluza	26	**	2	9	-	-	-	-	24	**
Gavreto	24	102	13	43	4	31	-	-	7	**
Luxturna	8	-31	8	-31	-	-	-	-	-	-
Columvi	5	-	5	-	-	-	-	-	-	-
Susvimo	1	-2	1	-2	-	-	-	-	-	-
Pharma other	1,853	-17	469	-36	283	-25	326	-2	775	-2
Pharma total sales	22,681	8	11,743	7	4,105	5	2,210	14	4,623	9

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022
Ocrevus	1,461	17	1,517	16	1,609	18	1,636	14	1,564	15
Hemlibra	973	31	952	23	1,045	24	1,034	24	1,053	17
Perjeta	1,068	9	1,029	5	997	4	1,049	11	1,033	6
Tecentriq	933	13	934	9	1,025	24	920	15	933	8
Actemra/RoActemra	663	-23	584	-42	662	-22	676	-12	620	2
Xolair	569	13	600	8	583	6	479	5	552	4
Kadcyla	563	18	516	6	490	-3	509	5	492	-5
Vabysmo	88	-	173	-	309	-	432	*	525	*
MabThera/Rituxan	553	-20	479	-19	479	-20	459	-17	423	-17
Herceptin	572	-11	493	-23	470	-22	477	-17	401	-22
Avastin	561	-27	510	-28	470	-25	416	-24	421	-17
Alecensa	384	16	382	11	386	10	372	9	386	11
Evryssi	274	65	293	93	326	59	363	62	342	36
Activase/TNKase	312	1	322	-5	296	-27	302	23	319	9
Ronapreve	22	-91	22	-92	1,048	118	567	9	-17**	-98
Phesgo	179	168	201	76	214	73	241	72	276	67
Gazyva	184	9	190	9	191	9	197	24	205	20
Polivy	96	93	113	63	147	97	150	96	203	129
Lucentis	316	-9	228	-39	212	-40	167	-35	132	-55
Pulmozyme	143	2	135	-3	129	-15	127	-5	111	-15

* Over 500%

**Effect of currency revaluation (CHF/JPY) on CHF567m Q1 2023 Ronapreve sales

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022
Ocrevus	1,090	10	1,143	17	1,204	15	1,188	13	1,158	14
Hemlibra	578	24	586	16	632	21	631	21	616	14
Perjeta	378	4	395	0	398	13	392	8	371	6
Tecentriq	505	15	500	3	524	20	507	14	493	5
Actemra/RoActemra	284	-31	250	-61	282	-42	296	-22	278	6
Xolair	569	13	600	8	583	6	479	5	552	4
Kadcyla	211	-1	204	-8	201	-4	198	-3	188	-5
Vabysmo	80	-	152	-	264	-	360	*	428	458
MabThera/Rituxan	344	-24	311	-14	314	-15	274	-21	260	-19
Herceptin	119	-29	113	-29	100	-29	91	-37	85	-23
Avastin	164	-36	155	-31	137	-26	133	-25	123	-20
Alecensa	108	14	124	22	122	13	106	7	115	14
Evrysdi	118	28	121	13	122	20	124	13	131	19
Activase/TNKase	297	1	305	-6	278	-29	288	23	304	9
Ronapreve	-	-	-	-	-	-	-	-	-	-
Phesgo	78	134	79	62	87	58	98	62	111	53
Gazyva	86	3	90	7	94	11	99	32	95	18
Polivy	43	97	44	57	44	65	46	35	78	91
Lucentis	316	-9	228	-39	212	-40	167	-35	132	-55
Pulmozyme	97	5	96	2	89	-17	83	-5	75	-16

* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022
Ocrevus	259	34	269	11	267	26	298	11	286	16
Hemlibra	190	29	182	36	199	27	206	27	213	18
Perjeta	229	-12	204	-15	210	-15	220	1	193	-12
Tecentriq	200	24	190	17	221	23	195	11	203	7
Actemra/RoActemra	200	-2	182	-3	200	-14	193	-8	190	0
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	178	12	158	3	163	-2	154	-6	144	-15
Vabysmo	-	-	4	-	18	-	44	-	59	*
MabThera/Rituxan	51	-16	51	-18	48	-21	51	0	45	-9
Herceptin	111	-9	96	-18	93	-27	97	-17	86	-18
Avastin	58	-49	42	-47	35	-56	30	-45	27	-51
Alecensa	74	8	69	5	74	3	73	3	75	5
Evryssi	84	227	101	216	100	116	113	74	128	61
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Ronapreve	3	-99	37	-54	-1	-100	-	-100	-	-100
Phesgo	87	188	100	107	104	61	114	59	126	55
Gazyva	49	-8	49	-9	48	-8	55	25	56	22
Polivy	24	30	38	88	48	144	40	93	40	76
Lucentis	-	-	-	-	-	-	-	-	-	-
Pulmozyme	25	-12	22	-12	23	-13	20	-16	19	-20

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	96	24	97	22	100	14	92	24	100	19
Perjeta	61	-1	55	-1	59	3	53	2	56	5
Tecentriq	111	-9	108	0	117	6	105	12	109	11
Actemra/RoActemra	87	-2	82	-4	86	6	77	0	80	5
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	36	20	33	16	30	2	26	-8	26	-17
Vabysmo	7	-	17	-	23	-	21	-	25	299
MabThera/Rituxan	9	-2	7	-13	8	-23	6	-13	7	-15
Herceptin	13	-27	12	-28	11	-28	9	-30	8	-34
Avastin	132	-13	115	-19	112	-21	91	-21	86	-25
Alecensa	60	5	55	4	59	7	50	5	57	7
Evrysdi	21	-	22	*	24	83	21	47	24	25
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Ronapreve	-16**	-	-15**	-100	1,028	313	567	33	-18***	-
Phesgo	-	-	-	-	-	-	-	-	-	-
Gazyva	13	-10	11	-17	11	-12	8	-35	12	1
Polivy	22	226	25	34	45	92	51	169	57	194
Lucentis	-	-	-	-	-	-	-	-	-	-
Pulmozyme	-	44	-	-1	1	38	-	18	-	-4

* Over 500%

Effect of currency revaluation (CHF/JPY) on CHF483m Q1 2022 (**) and on CHF567m Q1 2023 (***) Ronapreve sales

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q2 2022	% change vs. Q2 2021	Q3 2022	% change vs. Q3 2021	Q4 2022	% change vs. Q4 2021	Q1 2023	% change vs. Q1 2022	Q2 2023	% change vs. Q2 2022
Ocrevus	112	62	105	26	138	29	150	32	120	23
Hemlibra	109	115	87	53	114	45	105	38	124	31
Perjeta	400	37	375	30	330	13	384	22	413	18
Tecentriq	117	17	136	30	163	70	113	34	128	23
Actemra/RoActemra	92	-44	70	-44	94	51	110	10	72	-9
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	138	81	121	46	96	-3	131	42	134	11
Vabysmo	1	-	-	-	4	-	7	-	13	**
MabThera/Rituxan	149	-13	110	-32	109	-28	128	-12	111	-14
Herceptin	329	-3	272	-22	266	-17	280	-7	222	-22
Avastin	207	-17	198	-23	186	-16	162	-19	185	1
Alecensa	142	29	134	9	131	13	143	14	139	13
Evryydi	51	-5	49	231	80	73	105	189	59	39
Activase/TNKase	15	4	17	12	18	20	14	17	15	8
Ronapreve	35	-68	-	-99	21	-81	-	-100	1	-97
Phesgo	14	278	22	20	23	**	29	232	39	206
Gazyva	36	101	40	91	38	62	35	27	42	29
Polivy	7	145	6	135	10	86	13	340	28	339
Lucentis	-	-	-	-	-	-	-	-	-	-
Pulmozyme	21	14	17	-16	16	-9	24	10	17	-5

* Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

** Over 500%

9. Roche Group consolidated income statement for the six months ended 30 June 2023

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	22,681	7,098	-	29,779
Other revenue	806	31	-	837
Cost of sales	(4,457)	(3,474)	-	(7,931)
Research and development	(6,065)	(853)	-	(6,918)
Selling, general and administration	(3,588)	(1,381)	(1,881)	(6,850)
Other operating income and expense	708	146	(7)	847
Operating profit	10,085	1,567	(1,888)	9,764
Financing costs				(490)
Other financial income (expense)				(100)
Profit before taxes				9,174
Income taxes				(1,611)
Net income				7,563
Attributable to				
- Roche shareholders				7,137
- Non-controlling interests				426
Earnings per share and non-voting equity security				
Basic (CHF)				8.93
Diluted (CHF)				8.87

10. Roche Group core results reconciliation – Half Year 2023

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
Sales	29,779	-	-	-	-	-	-	-	-	29,779
Other revenue	837	-	-	-	-	-	-	-	-	837
Cost of sales	(7,931)	287	188	-	-	-	-	-	-	(7,456)
Research and development	(6,918)	54	155	260	-	-	-	-	-	(6,449)
Selling, general and administration	(6,850)	330	15	-	-	-	-	-	-	(6,505)
Other operating income and expense	847	7	-	-	1	(150)	-	-	-	705
Operating profit	9,764	678	358	260	1	(150)	-	-	-	10,911
Financing costs	(490)	-	-	-	3	5	-	-	-	(482)
Other financial income (expense)	(100)	-	-	-	-	-	-	-	-	(100)
Profit before taxes	9,174	678	358	260	4	(145)	-	-	-	10,329
Income taxes	(1,611)	(134)	(22)	(52)	-	46	-	-	31	(1,742)
Net income	7,563	544	336	208	4	(99)	-	-	31	8,587
Attributable to										
- Roche shareholders	7,137	515	334	202	4	(99)	-	-	31	8,124
- Non-controlling interests	426	29	2	6	-	-	-	-	-	463
EPS - diluted (CHF)	8.87	0.63	0.42	0.25	0.01	(0.12)	-	-	0.04	10.10

12. Roche Group consolidated balance sheet

in millions of CHF	30 June 2023	31 December 2022	31 December 2021
Non-current assets			
Property, plant and equipment	22,792	23,075	23,163
Right-of-use assets	1,103	1,133	1,249
Goodwill	10,564	10,820	10,809
Intangible assets	9,129	9,685	12,117
Deferred tax assets	6,667	6,427	5,583
Defined benefit plan assets	1,026	957	1,498
Other non-current assets	2,113	2,238	2,271
Total non-current assets	53,394	54,335	56,690
Current assets			
Inventories	8,496	8,605	7,715
Accounts receivable	11,089	11,606	10,806
Current income tax assets	270	313	320
Other current assets	3,612	3,525	3,755
Marketable securities	3,789	4,776	6,181
Cash and cash equivalents	3,720	4,991	6,850
Total current assets	30,976	33,816	35,627
Total assets	84,370	88,151	92,317
Non-current liabilities			
Long-term debt	(20,345)	(21,391)	(16,076)
Net deferred tax liabilities	(671)	(645)	(628)
Defined benefit plan liabilities	(4,403)	(4,561)	(6,103)
Provisions	(1,217)	(1,111)	(1,442)
Other non-current liabilities	(1,182)	(1,189)	(1,307)
Total non-current liabilities	(27,818)	(28,897)	(25,556)
Current liabilities			
Short-term debt	(5,041)	(3,960)	(15,122)
Current income tax liabilities	(3,576)	(3,187)	(3,002)
Provisions	(1,547)	(2,248)	(2,526)
Accounts payable	(4,055)	(4,556)	(4,637)
Other current liabilities	(11,989)	(13,288)	(13,129)
Total current liabilities	(26,208)	(27,239)	(38,416)
Total liabilities	(54,026)	(56,136)	(63,972)
Total net assets	30,344	32,015	28,345
Equity			
Capital and reserves attributable to Roche shareholders	26,515	27,992	24,489
Equity attributable to non-controlling interests	3,829	4,023	3,856
Total equity	30,344	32,015	28,345

13. Roche Group consolidated statement of cash flows

in millions of CHF	HY 2023	HY 2022
Cash flows from operating activities		
Cash generated from operations	12,091	14,522
(Increase) decrease in net working capital	(1,804)	(2,052)
Payments made for defined benefit plans	(314)	(290)
Utilisation of provisions	(505)	(527)
Disposal of products	-	-
Other operating cash flows	-	-
Cash flows from operating activities, before income taxes paid	9,468	11,653
Income taxes paid	(1,570)	(2,482)
Total cash flows from operating activities	7,898	9,171
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,740)	(1,685)
Purchase of intangible assets	(234)	(341)
Disposal of property, plant and equipment	33	38
Disposal of intangible assets	-	-
Disposal of products	585	338
Business combinations	-	(41)
Divestment of subsidiaries	-	-
Interest and dividends received	57	2
Sales of marketable securities	65	101
Purchases of marketable securities	(82)	(132)
Sales (purchases) of money market instruments and time accounts over three months, net	782	3,547
Other investing cash flows	52	(16)
Total cash flows from investing activities	(482)	1,811
Cash flows from financing activities		
Proceeds from issue of bonds and notes	1,238	7,642
Redemption and repurchase of bonds and notes	(645)	-
Increase (decrease) in commercial paper	(41)	1,802
Increase (decrease) in other debt	(19)	(13,527)
Hedging and collateral arrangements	139	(534)
Changes in ownership interests in subsidiaries	-	-
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	-	-
Interest paid	(368)	(228)
Principal portion of lease liabilities paid	(174)	(186)
Dividends paid	(7,789)	(7,672)
Equity-settled equity compensation plans, net of transactions in own equity	(633)	(611)
Other financing cash flows	(1)	(1)
Total cash flows from financing activities	(8,293)	(13,315)
Net effect of currency translation on cash and cash equivalents	(394)	(202)
Increase (decrease) in cash and cash equivalents	(1,271)	(2,535)
Cash and cash equivalents at beginning of period	4,991	6,850
Cash and cash equivalents at end of period	3,720	4,315